Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Common Equity (2020 - 2025)

Historic Common Equity for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • Biofrontera's Common Equity fell 14667.27% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 14667.27%. This contributed to the annual value of $4.4 million for FY2024, which is 751.1% down from last year.
  • Per Biofrontera's latest filing, its Common Equity stood at -$2.6 million for Q3 2025, which was down 14667.27% from -$4.7 million recorded in Q2 2025.
  • Biofrontera's 5-year Common Equity high stood at $23.9 million for Q4 2022, and its period low was -$17.4 million during Q3 2021.
  • For the 5-year period, Biofrontera's Common Equity averaged around $6.6 million, with its median value being $5.2 million (2023).
  • As far as peak fluctuations go, Biofrontera's Common Equity surged by 43275.53% in 2024, and later tumbled by 14667.27% in 2025.
  • Quarter analysis of 5 years shows Biofrontera's Common Equity stood at $11.3 million in 2021, then surged by 110.6% to $23.9 million in 2022, then crashed by 79.93% to $4.8 million in 2023, then dropped by 7.51% to $4.4 million in 2024, then tumbled by 158.22% to -$2.6 million in 2025.
  • Its Common Equity stands at -$2.6 million for Q3 2025, versus -$4.7 million for Q2 2025 and $500000.0 for Q1 2025.